Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

GlaxoSmithKline plc GSK announced that the FDA has granted approval to Nucala as an add-on treatment for severe eosinophilic asthma in the pediatric patient population, aged six to 11 years, in the United States. The drug is already marketed in the United States and EU for severe eosinophilic asthma patients aged 12 years or older. In the EU, it had received approval for pediatric use (from aged six-17 years) in August last year.